| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Devanand Sarkar | Q92257536 |
| P2093 | author name string | Saranya Chidambaranathan Reghupaty | |
| P2860 | cites work | Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology | Q24616987 |
| Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma | Q26772315 | ||
| EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features | Q30493364 | ||
| Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma | Q91140207 | ||
| The long noncoding RNA GAS8-AS1 suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor GAS8 | Q91517632 | ||
| Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL | Q91526947 | ||
| Vps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma | Q91791939 | ||
| Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells | Q91845711 | ||
| MicroRNA-214 suppresses cell proliferation and migration and cell metabolism by targeting PDK2 and PHF6 in hepatocellular carcinoma | Q92070618 | ||
| YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway | Q92135433 | ||
| lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway | Q92334347 | ||
| A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells | Q92562439 | ||
| MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2 | Q92591768 | ||
| miR-21-5p Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting FASLG | Q92933973 | ||
| Long non‑coding RNA Fer‑1‑like family member 4 suppresses hepatocellular carcinoma cell proliferation by regulating PTEN in vitro and in vivo | Q93090443 | ||
| Tisagenlecleucel (Kymriah) for ALL | Q95414079 | ||
| Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial | Q33379689 | ||
| Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma | Q33670826 | ||
| miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma | Q33685465 | ||
| Magnetic Cationic Amylose Nanoparticles Used to Deliver Survivin-Small Interfering RNA for Gene Therapy of Hepatocellular Carcinoma In Vitro | Q33742235 | ||
| Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells | Q33779147 | ||
| Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis | Q33851416 | ||
| The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma | Q34162174 | ||
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement | Q34324970 | ||
| Genetic deletion of AEG-1 prevents hepatocarcinogenesis. | Q34438436 | ||
| Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma | Q34517734 | ||
| Glypican-3: A new target for cancer immunotherapy | Q34543102 | ||
| Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice | Q34685225 | ||
| Meta-analysis: prognostic value of survivin in patients with hepatocellular carcinoma | Q35080302 | ||
| Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles | Q35129862 | ||
| Inhibitory effect of midkine-binding peptide on tumor proliferation and migration | Q35697310 | ||
| The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. | Q35742449 | ||
| MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer | Q35781512 | ||
| Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells | Q35878681 | ||
| NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery | Q35995828 | ||
| Lentivirus-Mediated siRNA Targeting ER-α Inhibits Tumorigenesis and Induces Apoptosis in Hepatocarcinoma Cells | Q36043477 | ||
| YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression | Q36048228 | ||
| Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and αVβ3 Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells | Q36071406 | ||
| Prognostic value of Notch-1 expression in hepatocellular carcinoma: a meta-analysis | Q36212694 | ||
| Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition | Q36414180 | ||
| Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). | Q36664787 | ||
| Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model | Q36792563 | ||
| microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma | Q36843809 | ||
| CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425 | Q36946723 | ||
| Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma | Q37269190 | ||
| Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor | Q37275063 | ||
| Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice | Q37609755 | ||
| Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma | Q37644875 | ||
| Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression | Q37694786 | ||
| Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma | Q37742979 | ||
| Delivery approaches of gene therapy in hepatocellular carcinoma | Q38162139 | ||
| Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma | Q38304400 | ||
| Features and treatment options of Chinese hepatocellular carcinoma | Q38405694 | ||
| A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma | Q38425231 | ||
| Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target | Q38450536 | ||
| Survivin in survival of hepatocellular carcinoma | Q38539399 | ||
| miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma | Q38708527 | ||
| The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery | Q38743823 | ||
| miR-154 targeting ZEB2 in hepatocellular carcinoma functions as a potential tumor suppressor | Q38824771 | ||
| Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis. | Q38825657 | ||
| Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. | Q38832724 | ||
| Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. | Q38841311 | ||
| Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions | Q38865803 | ||
| The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) | Q38924552 | ||
| CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway | Q38997953 | ||
| Impact of Mucin1 knockdown on the phenotypic characteristics of the human hepatocellular carcinoma cell line SMMC-7721. | Q39003677 | ||
| PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. | Q40100942 | ||
| Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma | Q40564910 | ||
| Circulating CD147 predicts mortality in advanced hepatocellular carcinoma | Q40602159 | ||
| Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. | Q41602780 | ||
| HAb18G/CD147 promotes radioresistance in hepatocellular carcinoma cells: a potential role for integrin β1 signaling | Q41656918 | ||
| Lentivirus-mediated knockdown of P27RF-Rho inhibits hepatocellular carcinoma cell growth | Q41824679 | ||
| Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. | Q41847265 | ||
| Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. | Q42208584 | ||
| Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)‑2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway | Q43768119 | ||
| Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma. | Q45057498 | ||
| Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma | Q45865976 | ||
| Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells. | Q45872805 | ||
| Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy | Q45874029 | ||
| Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. | Q45982820 | ||
| MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. | Q47134775 | ||
| Long Non-Coding RNA Linc-USP16 Functions As a Tumour Suppressor in Hepatocellular Carcinoma by Regulating PTEN Expression | Q47407961 | ||
| Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway | Q48024895 | ||
| Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma | Q48140297 | ||
| Chitosan-lipid nanoparticles (CS-LNPs): Application to siRNA delivery | Q49961175 | ||
| Lentivirus-mediated shRNA Targeting CNN2 Inhibits Hepatocarcinoma in Vitro and in Vivo | Q50050554 | ||
| miR-30e acts as a tumor suppressor in hepatocellular carcinoma partly via JAK1/STAT3 pathway. | Q50611939 | ||
| Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. | Q50910382 | ||
| Engineering Well-Characterized PEG-Coated Nanoparticles for Elucidating Biological Barriers to Drug Delivery. | Q51021223 | ||
| Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. | Q51825252 | ||
| A novel long noncoding RNA lncWDR26 suppresses the growth and metastasis of hepatocellular carcinoma cells through interaction with SIX3. | Q55002362 | ||
| An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma. | Q55265288 | ||
| MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling | Q57128364 | ||
| Chitosan-Based Nanomaterials for Drug Delivery | Q58557680 | ||
| Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress | Q58765234 | ||
| Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression | Q58768388 | ||
| Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1 | Q64059929 | ||
| LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells | Q64108069 | ||
| GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy | Q64277509 | ||
| Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma | Q73638685 | ||
| [Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby] | Q81440054 | ||
| miR-1247-5p functions as a tumor suppressor in human hepatocellular carcinoma by targeting Wnt3 | Q88247140 | ||
| Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma | Q88889077 | ||
| Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules | Q88906125 | ||
| The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis | Q89218611 | ||
| Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma | Q90414183 | ||
| Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA | Q90755534 | ||
| Gankyrin as a potential target for tumor therapy: evidence and perspectives | Q90860782 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P577 | publication date | 2019-08-28 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Current Status of Gene Therapy in Hepatocellular Carcinoma | |
| P478 | volume | 11 |
| Q89834935 | Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma |
| Q90723462 | Glycyrrhizin Acid and Glycyrrhetinic Acid Modified Polyethyleneimine for Targeted DNA Delivery to Hepatocellular Carcinoma |
| Q90382795 | The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease |
| Q95847957 | siVEGF-loaded nanoparticle uptake by tumor-associated vascular endothelial cells for hepatocellular carcinoma |
Search more.